Long-Term Prognosis of Acute Myeloid Leukemia According to the New Genetic Risk Classification of the European LeukemiaNet Recommendations: Evaluation of the Proposed Reporting System

Röllig, Christoph; Bornhäuser, Martin; Thiede, Christian; Taube, Franziska; Kramer, Michael; Mohr, Brigitte; Aulitzky, Walter E.; Bodenstein, H.; Tischler, Hans-Joachim; Stuhlmann, Reingard; Schuler, Ulrich S.; Stölzel, Friedrich; Bonin, Malte von; Wandt, Hannes; Schäfer‐Eckart, Kerstin; Schaich, Markus; Ehninger, Gerhard

doi:10.1200/jco.2010.32.8500

Cited by 217 publications

(183 citation statements)

References 32 publications

Supporting

Mentioning

175

Contrasting

Order By: Relevance

“…At present, therapy decisions are guided by pre-therapeutic risk assessments. 1 Nevertheless, there are still patients who suffer from relapse despite belonging to the favorable risk group 2,3 and more individualized therapy regimens are needed to prevent relapses.…”

Section: Introductionmentioning

confidence: 99%

Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse

Hubmann¹,

Köhnke²,

Hoster

et al. 2014

Haematologica

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse

Hubmann¹,

Köhnke²,

Hoster

et al. 2014

Haematologica

View full text Add to dashboard Cite

“…The most recent review of the cytogenetic classification by an international expert panel on behalf of the ELN has been published in 2010 and validated in large series. 6,7 The adverse-risk group comprises the recurrent lesions inv(3)(q21q26.2) or t(3;…”

Section: Introductionmentioning

confidence: 99%

Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl(17p) and −5/5q−

Middeke

Beelen

Stadler

et al. 2012

Blood

Self Cite

View full text Add to dashboard Cite

The European LeukemiaNet classification combines a heterogeneous group of aberrations as adverse-risk abnormalities. Our goal was to investigate the outcomes associated with distinct high-risk chromosomal abnormalities in acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (HSCT). We performed a retrospective cohort analysis in patients with high-risk AML who received first, HLA-compatible, allogeneic HSCT between January 2005 and December 2008. Data from 236 patients with a median age of 55 years were included. Because complex karyotype (CK), ؊5/5q؊, and abnl(17p) are overlapping categories, a hierarchical classification system based on the presence or absence of abnl(17p) and ؊5/5q؊ was developed. Patients with abnl(17p) had a 2-year event-free survival (EFS) of 11% (95% confidence interval [CI], 0%-25%), patients with ؊5/5q؊ but no abnl(17p) a 2-year EFS of 29% (95% CI, 14%-44%), and patients with adverse-risk AML but neither of the 2 marker lesions a 2-year EFS of 49% (95% CI, 39%-59%). Notably, complex and monosomal karyotypes lost their prognostic value when these marker lesions were excluded. In conclusion, hierarchical classification of adverse-risk karyotypes by 2 marker lesions, abnl(17p) and ؊5/5q؊, is effective in prognostication of the outcome of alloge-

show abstract

“…This results in clonal expansion and accumulation of immature myeloid cells in the bone marrow that fail to differentiate further into normal functional cells. Currently, genetic abnormalities found at diagnosis are used to classify the disease in subgroups and to assess patients' risk [3,4]. These genetic abnormalities serve as important targets for drug therapy.…”

Section: Introductionmentioning

confidence: 99%

Targeting the mitochondria in acute myeloid leukemia

Sánchez-Mendoza

Rego

2017

Appl Cancer Res

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) is a clonal hematologic neoplasm characterized by heterogeneity of genetic abnormalities found at diagnosis. These abnormalities serve to classify patients by risk group into low, intermediate, and high risk. It also provides specific targets for the development of new combinational therapies. However, because of the heterogeneity of genetic abnormalities, targeted therapy is not always possible. Altered mitochondrial metabolism is a common feature in cancer cells, a phenomenon first described by Otto Warburg. In AML patients, the discovery of mutations in the isocitrate dehydrogenase gene provided for the first time a link between altered mitochondrial metabolism and AML. This raised the possibility of testing drugs known as mitocans for new combinational therapeutic approaches. Mitocans are a diverse group of anti-cancer compounds that target mitochondria. They disrupt energy production leading to enhanced generation of reactive oxygen species along with the activation of the intrinsic pathway of apoptosis. The present review discusses the different types of mitocans and their mechanism of action along with preclinical and clinical studies in AML.

show abstract

Long-Term Prognosis of Acute Myeloid Leukemia According to the New Genetic Risk Classification of the European LeukemiaNet Recommendations: Evaluation of the Proposed Reporting System

Cited by 217 publications

References 32 publications

Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse

Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse

Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl(17p) and −5/5q−

Targeting the mitochondria in acute myeloid leukemia

Contact Info

Product

Resources

About